From Anaheim, Calif., at a meeting of the American Chemical Society
In an effort to stem the increasing prevalence of type 1 diabetes, researchers are developing a drug that could protect susceptible individuals from the disease.
People with type 1 diabetes need frequent insulin injections to control their blood sugar because their immune system has destroyed the insulin-producing cells in their pancreas. One of the proteins in the cascade of reactions responsible for killing pancreatic cells is called macrophage migration inhibitory factor (MIF).
Science News headlines, in your inbox
Headlines and summaries of the latest Science News articles, delivered to your email inbox every Thursday.
Thank you for signing up!
There was a problem signing you up.
Medicinal chemist Yousef Al-Abed of the North Shore–Long Island Jewish Research Institute in Manhasset, N.Y., led recent effort in which he and his colleagues identified a compound, called ISO-1, that blocks the activity of MIF. When the researchers treated mice genetically altered to develop diabetes, a 10-day course of the drug prevented the disease’s onset in 90 percent of the mice. What’s more, the drug’s protective effects lasted up to 2 months after the treatment ended.
Although several research groups are developing drugs for prevention, most have concentrated on antibody-based vaccines. Any successful antibody vaccine will require trained health care workers to administer multiple injections, Al-Abed says. Because ISO-1 is a small molecule, it could be taken in a pill and have long-lasting effects.
Candidates for the treatment would include people with certain protein or gene markers in their blood that predict increased risk of diabetes, says Al-Abed, but he cautions that it could be 10 years before ISO-1 reaches patients.